212 related articles for article (PubMed ID: 11147086)
1. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
Tanghetti EA;
Cutis; 2000 Dec; 66(6 Suppl):12-8. PubMed ID: 11147086
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
Coynik D
Cutis; 2000 Dec; 66(6 Suppl):19-24. PubMed ID: 11147087
[TBL] [Abstract][Full Text] [Related]
3. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
4. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.
Tanghetti EA;
Cutis; 2000 Dec; 66(6 Suppl):4-11. PubMed ID: 11147088
[TBL] [Abstract][Full Text] [Related]
5. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
6. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Poulin YP
Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
[TBL] [Abstract][Full Text] [Related]
7. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
9. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
12. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.
Singh S; Reddy DC; Pandey SS
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):61-5. PubMed ID: 10863225
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of tazarotene: optimizing clinical results.
Lebwohl M
Cutis; 1998 Feb; 61(2 Suppl):27-9. PubMed ID: 9787989
[TBL] [Abstract][Full Text] [Related]
14. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
15. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
[TBL] [Abstract][Full Text] [Related]
16. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
Lebwohl M; Colón LE
Cutis; 2007 Nov; 80(5 Suppl):29-40. PubMed ID: 18154221
[TBL] [Abstract][Full Text] [Related]
17. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis.
Green L; Sadoff W
J Cutan Med Surg; 2002; 6(2):95-102. PubMed ID: 11992180
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
Tirado-Sánchez A; Ponce-Olivera RM
Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
[TBL] [Abstract][Full Text] [Related]
19. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study.
Huang YC; Chou CL; Chiang YY
Lasers Surg Med; 2013 Feb; 45(2):102-7. PubMed ID: 23423871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
